HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach (Q41757403)

8 October 2017

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach (English)

1 reference

8 October 2017

1 reference

Ridolfi RL

1

1 reference

8 October 2017

Jamehdor MR

series ordinal

2

1 reference

8 October 2017

Arber JM

series ordinal

3

1 reference

8 October 2017

1 August 2000

1 reference

8 October 2017

1 reference

8 October 2017

13

1 reference

8 October 2017

8

1 reference

8 October 2017

866-873

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.3880154

8 October 2017

0 references

cites work

Critical determination of the frequency of c-erbB-2 amplification in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

Assessment of antigen damage in immunohistochemistry. The vimentin internal control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

Analysis of cerbB2 expression using a panel of 6 commercially available antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

7 January 2021

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

7 January 2021

c-erbB-2 and c-erbA-1 (ear-1) gene amplification and c-erbB-2 protein expression in Japanese breast cancers: their relationship to the histology and other disease parameters.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

7 January 2021

The HercepTest assay: another perspective

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

7 January 2021

No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

7 January 2021

C-ERBB-2 oncogens protein inIn situ and invasive lobular breast neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

7 January 2021

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880154

7 January 2021

10.1038/MODPATHOL.3880154

Identifiers

DOI

1 reference

Dimensions Publication ID

8 October 2017

1033626551

0 references

Fatcat ID

release_oly6pywrn5h5rkvi66dej3oun4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oly6pywrn5h5rkvi66dej3oun4

24 November 2022

mapped directly with Wikidata item

1 reference